Oncology and Hematology - Prova Education

129-144 of 163

Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and Hematology
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and Hematology
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and Hematology
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and Hematology
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CE
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
0.25 credits
- Meghan Mooradian, MD
0.25 credits
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
0.25 credits
- Benjamin Levy, MD
- Alexander Spira, MD, PhD, FACP
0.25 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
0.25 credits
- Helena Yu, MD
0.25 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
0.50 credits
- Jyoti Patel, MD
- Pasi Antero Jänne, MD, PhD
0.50 credits
Advances in Minimally Invasive Screening for Lung Cancer
Advances in Minimally Invasive Screening for Lung Cancer
CME/CE
Advances in Minimally Invasive Screening for Lung Cancer
0.25 credits
- Julie A. Barta, MD, ATSF
- Peter J. Mazzone, MD, MPH, FCCP
0.25 credits
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
CME/CE
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
- Thomas F. Patterson, MD, FACP, FIDSA
- George Thompson III, MD, FIDSA
Invasive Fungal Infections: More Common Than You Think
Invasive Fungal Infections: More Common Than You Think
CME/CE
Invasive Fungal Infections: More Common Than You Think
- Peter G. Pappas, MD, FACP
- Thomas F. Patterson, MD, FACP, FIDSA
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Drug Information Updates
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
Medical Breakthroughs from Penn Medicine
CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
- Shira Johnson, MD
- Robert Vonderheide, MD
Pancreatic Cancer: The Hunt to Catch a Silent Killer
Pancreatic Cancer: The Hunt to Catch a Silent Killer
Project Oncology®
Pancreatic Cancer: The Hunt to Catch a Silent Killer
- John Russell, MD
- Harish Lavu, MD

9/8